Table 3.

Associations between aspirin use and statins use and the presence and extent of intraprostatic inflammation in a subset^a of men from the placebo arm of PCPT

	Aspirin Use			Statins Use
	At least one core with inflammation			At least one core with inflammation
	No	Yes		No	Yes
# users / non-users	70 / 50	148 / 89		37 / 83	78 / 159
Model 1 OR (95% CI)	Ref	1.19 (0.76–1.86)		Ref	1.10 (0.69–1.77)
Model 2 OR (95% CI)	Ref	1.11 (0.70–1.75)		Ref	1.02 (0.63–1.65)
Model 3 OR (95% CI)	Ref	1.16 (0.71–1.89)		Ref	1.04 (0.62–1.73)
	Percent of cores with inflammation			Percent of cores with inflammation
	None	Some	All	None	Some	All
# users / non-users	70 / 52	135 / 73	13 / 14	35 / 73	63 / 124	6 / 16
Model 1 OR (95% CI)	Ref	1.14 (0.87–2.17)	0.69 (0.30–1.59)	Ref	1.12 (0.69–1.81)	0.77 (0.30–1.99)
Model 2 OR (95% CI)	Ref	1.29 (0.81–2.06)	0.61 (0.26–1.43)	Ref	1.04 (0.63–1.70)	0.67 (0.26–1.75)
Model 3 OR (95% CI)	Ref	1.33 (0.81–2.19)	0.67 (0.26–1.70)	Ref	1.01 (0.60–1.70)	0.92 (0.33–2.56)
	Mean percent tissue area with inflammation			Mean percent tissue area with inflammation
	None	<3%	≥3%	None	<3%	≥3%
# users / non-users	70 / 50	75 / 42	73 / 47	37 / 83	43 / 74	35 / 85
Model 1 OR (95% CI)	Ref	1.28 (0.76–2.15)	1.11 (0.66–1.86)	Ref	1.30 (0.76–2.24)	0.92 (0.53–1.61)
Model 2 OR (95% CI)	Ref	1.21 (0.70–2.06)	1.02 (0.61–1.73)	Ref	1.23 (0.71–2.15)	0.84 (0.48–1.47)
Model 3 OR (95% CI)	Ref	1.21 (0.68–2.13)	1.12 (0.64–1.95)	Ref	1.23 (0.67–2.20)	0.87 (0.48–1.58)

^aFrom a case-control study of LUTS nested in the placebo arm of PCPT (5). The men did not have a clinical indication for biopsy.

Model 1: unadjusted

Model 2: adjusted for age and race

Model 3: adjusted for age (continuous), race (white, non-white), BMI (continuous), smoking status (current, former, never), physical activity (sedentary, light, moderate, active), education (college, no college), diabetes (yes, no), and statins use (for aspirin model) or aspirin use (for statins model) (yes, no)

PCPT, Prostate Cancer Prevention Trial; OR, odds ratio; CI, confidence interval